Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser

This study has been completed.
Sponsor:
Collaborator:
Fresenius Medical Care Deutschland GmbH
Information provided by (Responsible Party):
Andreas Bock, Kantonsspital Aarau
ClinicalTrials.gov Identifier:
NCT01578421
First received: April 12, 2012
Last updated: August 6, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2012
  Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)